Cellebrite DI Ltd. CLBT
What this company does
Written from the business description in Cellebrite DI Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at +19.5% a year over five years — but profit grew faster: net income at +68.4%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 19 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 |
| Operating income $B | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| EBITDA $B | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.1 | −0.3 | −0.1 | 0.1 | 0.1 | 0.0 | −0.0 |
| Free cash flow $B | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 |
| EPS, diluted $ | 0.31 | −1.35 | −0.43 | 0.59 | 0.44 | −0.08 | −0.08 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | −0 | 0 | 140 | 173 | −1333 |
| ROE % | 19.1 | −152.9 | −150.1 | 46642.9 | · | 9.4 | −3.2 |
| Shares out B | 0.25 | 0.23 | 0.20 | 0.19 | 0.19 | 0.12 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.